Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells 9,074 Shares of Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Catriona Yale sold 9,074 shares of the business’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $29.11, for a total transaction of $264,144.14. Following the completion of the transaction, the insider now owns 95,648 shares of the company’s stock, valued at $2,784,313.28. This represents a 8.66 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Catriona Yale also recently made the following trade(s):

• On Friday, November 15th, Catriona Yale sold 9,061 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.73, for a total transaction of $251,261.53.
• On Friday, November 1st, Catriona Yale sold 15,485 shares of Akero Therapeutics stock. The shares were sold at an average price of $32.62, for a total transaction of $505,120.70.
• On Wednesday, October 30th, Catriona Yale sold 4,515 shares of Akero Therapeutics stock. The stock was sold at an average price of $32.53, for a total transaction of $146,872.95.
• On Monday, October 14th, Catriona Yale sold 6,136 shares of Akero Therapeutics stock. The shares were sold at an average price of $30.03, for a total value of $184,264.08.
• On Friday, September 20th, Catriona Yale sold 5,500 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.65, for a total value of $152,075.00.

Akero Therapeutics Stock Performance

Shares of AKRO stock traded down $1.90 during mid-day trading on Wednesday, reaching $28.71. The stock had a trading volume of 742,147 shares, compared to its average volume of 842,461. Akero Therapeutics, Inc. has a 1-year low of $15.32 and a 1-year high of $37.00. The firm has a market cap of $2.00 billion, a price-to-earnings ratio of -7.66 and a beta of -0.23. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to-equity ratio of 0.05. The business’s fifty day moving average is $30.91 and its 200-day moving average is $27.36.

Akero Therapeutics (NASDAQ:AKRO) last issued its quarterly earnings results on Friday, November 8th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.15). On average, research analysts forecast that Akero Therapeutics, Inc. will post -3.96 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $50.00 price target on shares of Akero Therapeutics in a report on Monday, November 18th. Citigroup initiated coverage on shares of Akero Therapeutics in a research report on Monday, November 18th. They issued a “buy” rating and a $65.00 price objective for the company. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $46.83.

Institutional Trading of Akero Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. boosted its position in Akero Therapeutics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company’s stock worth $71,000 after purchasing an additional 446 shares in the last quarter. Y Intercept Hong Kong Ltd lifted its stake in shares of Akero Therapeutics by 13.8% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 16,916 shares of the company’s stock valued at $485,000 after purchasing an additional 2,049 shares during the period. Handelsbanken Fonder AB boosted its holdings in Akero Therapeutics by 12.4% during the third quarter. Handelsbanken Fonder AB now owns 20,000 shares of the company’s stock worth $574,000 after buying an additional 2,200 shares in the last quarter. LMR Partners LLP boosted its holdings in Akero Therapeutics by 17.0% during the third quarter. LMR Partners LLP now owns 20,597 shares of the company’s stock worth $591,000 after buying an additional 2,997 shares in the last quarter. Finally, Eastern Bank purchased a new stake in shares of Akero Therapeutics during the 3rd quarter worth about $100,000.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.